Gemtuzumab ozogamicin (solution)_product_DataBase

Bioactivity	Gemtuzumab ozogamicin (solution) is an antibody-drug conjugate (ADC) consisting of a humanized immunoglobulin (IgG4) antibody directed against CD33 that is conjugated to the cytotoxic agent Calicheamicin (HY-19609). Calicheamicin is a cytotoxic antibiotic. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia (AML)[1][2].
Invitro	Gemtuzumab ozogamicin (1-250 ng/mL; 72 小时) 对 CD33 阳性细胞具有细胞毒性[1]。Gemtuzumab ozogamicin 是一种 ADC。抗体与 CD33 结合并随后内化后，Gemtuzumab ozogamicin 主要通过诱导 DNA 损伤和随后的细胞凋亡来介导对 CD33 阳性骨髓细胞的细胞毒性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Gemtuzumab ozogamicin (solution) 相关抗体: Cell Viability Assay[1] Cell Line:
CAS	220578-59-6
Molar Mass	151000 (average)
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Yi Liu, et al. CD33-directed immunotherapy with third-generation chimeric antigen receptor T cells and gemtuzumab ozogamicin in intact and CD33-edited acute myeloid leukemia and hematopoietic stem and progenitor cells. Int J Cancer. 2022 Apr 1;150(7):1141-1155. [2]. Baron J, et al. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia. Expert Rev Clin Pharmacol. 2018;11(6):549-559.

PeptideDB